Pfizer’s Ibrance And The Realities Of 'Real-World' Evidence

 
• By Michael McCaughan
  
Boy-virtual-glasses
The US FDA's reliance on real-world evidence may have been less than meets the eye in the case of the supplemental indication for Pfizer’s Ibrance.

More from Approval Standards

More from Pathways & Standards